WG
RXRX icon

Winton Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Winton Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708K Buy
192,800
+88,700
+85% +$295K 0.02% 598
2026
Q1 		$320K Buy
+104,100
New +$402K 0.01% 843

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Winton Group's RXRX Position: Q2 2026 in Review

Winton Group increased its Recursion Pharmaceuticals (RXRX) stake by 85% in Q2 2026, buying an estimated $295K and bringing the position to 192,800 shares worth $708K. The position accounts for 0.02% of the portfolio, ranked #598.

Winton Group first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 341 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Winton Group held 192,800 shares of Recursion Pharmaceuticals worth $708K as of Q2 2026.
  • Winton Group bought 88,700 Recursion Pharmaceuticals shares in Q2 2026, an estimated $295K.
  • Recursion Pharmaceuticals made up 0.02% of Winton Group's portfolio in Q2 2026, its #598 holding.
  • Winton Group first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 341 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.